Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conditioning Regimens for HSCT in Pediatric AML/MDS
NCT02626715Phase 2Completed
- Start
- Sep 2015
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies, Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab, hydroxyurea, fludarabine, melphalan, thiotepa in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS). Started Sep 2015; status: completed.
02
Drugs
alemtuzumabhydroxyureafludarabinemelphalanthiotepa
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02626715.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02626715.